Last week, the U.S. Food and Drug Administration (FDA) approved the use of Darzalex Faspro (daratumumab and ...

Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat ...

The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...

Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...

Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while underscoring the need for strategies that optimize long-term tolerability, immune ...

Nocturnal symptoms and musculoskeletal pain are filtered through relapse fear, driving repetitive interpretation of ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

Multiple myeloma is the second most common blood cancer in the United States, and it is more common in men, with an estimated 20,030 new male cases diagnosed in 2025. Multiple myeloma is the ...